Ivax Starts Shipping Generic Paclitaxel; Oral Formulation Paxoral In Phase II
Executive Summary
Ivax has started shipping its generic version of Bristol's injectable anti-tumor agent Taxol (paclitaxel), Ivax President Neil Flanzraich told the CIBC World Markets Healthcare Conference in New York City Oct. 25.
You may also be interested in...
Qvar Sales Reps Grow To 200; Ivax Sees Outlicensing Opportunities From R&D
Ivax will have 200 sales reps to promote Qvar and its other respiratory products by the end of the year, President Neil Flanzraich said in Ivax's third quarter conference call Oct. 29
Qvar Sales Reps Grow To 200; Ivax Sees Outlicensing Opportunities From R&D
Ivax will have 200 sales reps to promote Qvar and its other respiratory products by the end of the year, President Neil Flanzraich said in Ivax's third quarter conference call Oct. 29
Taxol Generic Dispute Continues: Ivax Wins Ruling In L.A., Loses In D.C.
American Bioscience Inc. plans to move forward with the Washington, D.C. federal court to implement an appellate decision that could reverse the approval of generic paclitaxel